This phase II study demonstrated the efficacy of osimertinib 80 mg daily in patients with EGFR mutant NSCLC with leptomeningeal disease. The study designed included BICR using the RANO-LM assessment ...

The antihistamine desloratadine displays a two-step, reversible single-crystal to single-crystal phase transition during heating/cooling cycles between three conformational polymorphs: the low ...

Today James is looking at the cheapest 240mm AIO cooler we have ever reviewed - the Cougar Aqua 240. Coming in at ... likes of the Arctic Liquid Freezer II or Deepcool Castle 240EX?

Solana (SOL) stands out, and it's no secret why ... Solana plans to enhance Layer 1 and Layer 2 in 2025 to scale. Following the FTX crash, Solana revived many of its core projects, attracting ...

When Do Horrific Visions Start in Patch 11.1.5? Horrific Visions will return starting on May 20th after the weekly reset. This system returns in a form similar to their initial appearance in ...

Confirmation of size and scope of Phase 3 clinical program and associated safety database to support proposed indication in knee osteoarthritis Confirmation of pivotal study design, including ...

Today, a brief rundown of news involving Tourmaline Bio, Schrödinger and Beckley Psytech, as well as updates from CRISPR Therapeutics and Regenxbio that you may have missed. A growing cohort of ...

Confirmation of size and scope of Phase 3 clinical program and associated safety database to support proposed indication in knee osteoarthritis Confirmation of pivotal study design, including primary ...

During a recent appearance on the “Busted Open Radio” podcast, Sol Ruca commented on the start of her wrestling ... Natalya commented on a possible WWE Evolution 2 all-women’s event. You can check out ...

The most common adverse events reported from a four-week Phase 2 study were dry mouth, insomnia, and urinary hesitancy. Apnimed said full Phase 3 results will be presented at a medical meeting ...

There were no serious adverse events related to AD109 in the trial, Apnimed said in the release, with the safety profile resembling that of the candidate’s earlier, also successful phase 2 trial.

Randomized double-blind phase II study of maintenance pembrolizumab versus placebo after first-line chemotherapy in patients (pts) with metastatic urothelial cancer (mUC): HCRN GU14-182. GC score* for ...